Abstract
Abstract This double-blind, crossover, Phase III study compared 86C (acyclovir) cream 5% with Zovirax® (acyclovir) cream 5% in patients with recurrent herpes labialis. Both in vitro skin penetration tests and a guinea pig skin model infected with herpes simplex virus type 1 have shown a significantly shorter healing time with 86C than with Zovirax. The aim of our study was to establish if this difference could be confirmed in patients suffering from recurrent herpes labialis. The patients had to experience two complete attacks of herpes labialis during the study, and were instructed to start the antiviral treatment at the very early prodromal symptoms and each attack. Cream was applied to the lesion five times daily for 5 days. Results of 59 assessable patients showed no significant difference between the two cream formulations. The number of half days to healing was 10.47 for 86C and 10.12 for Zovirax. A total of 20 patients preferred 86C, 26 patients preferred Zovirax, and 13 patients had no drug preference. Both drugs were shown to be efficacious and safe. No adverse events occurred in this study.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have